NewTimeSpace News: MicroPort NeuroScientific Corporation (02172.HK) announced that the NUMEN™ Helia Coil Embolization System, independently developed by its subsidiary MicroPort NeuroTech (Shanghai) Co., Ltd., has recently received marketing approval from the U.S. Food and Drug Administration (FDA). This marks the Group’s third coil product approved for marketing in the U.S., following the NUMEN™ Detachable Coil and NUMEN™ Silk 3D Electrolytic Detachable Coil.
Although the Hong Kong market was closed for a public holiday on May 25, the AI LLM supply chain has remained the market's strongest driving force throughout the month, with KNOWLEDGE ATLAS (02513.HK) and MININGLAMP-W (02718.HK) surging 47.70% and 21.01% month-to-date, respectively.
China's AI industry has been experiencing a comprehensive resonance extending from macro policies to micro financial data. Weighty documents from the State Council made it clear that artificial intelligence legislation is accelerating, the National Development and Reform Commission (NDRC) is planning to issue supporting documents for "AI+", ByteDance has increased its AI capital expenditure, and both Zhipu and MiniMax have been included in the Hang Seng Tech Index. Following the NDRC press conference on May 22, Hong Kong-listed AI concept stocks shot up in a straight line. Zhipu (2513.HK) once surged over 30%, hitting another historical high, while MINIMAX (0100.HK), Mininglamp Technology-W (2718.HK), and Xunce (3317.HK) all rallied strongly.
On May 22, Hong Kong stocks rebounded, with the Hang Seng Index (HSI) rising 0.86% and the Hang Seng TECH Index surging 2.11%. The AI supply chain emerged as the main driving force: ZHIPU AI soared nearly 27%, MINIMAX jumped over 15%, Lenovo Group skyrocketed by 19.8%, and 51World surged 28.9%. In industry news, reports indicated that OpenAI is preparing for an IPO with Q1 revenue reaching approximately USD 5.7 billion; ZHIPU AI launched its GLM-5.1 HighSpeed API with an output speed of 400 tokens/s; and Tencent will host its first-ever Public Open Day from May 30 to 31.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the first patient has been dosed in the Phase I clinical research of self-developed injectable HLX316, a B7-H3-targeting sialidase Fc fusion protein, for advanced and metastatic solid tumors in China. As an innovative first-in-class B7-H3-targeting sialidase heterodimer, no equivalent product has obtained marketing approval globally.
Recently, enterprises related to large language models have entered a period of intensive product releases. A multi-polar, multi-functional application landscape is unfolding across the board.Catalyzed by industry and company news, stocks related to the large model concept have performed well this week. As of the market close on May 22, Zhipu saw a weekly gain of over 20%, Mininglamp Technology-W rose over 10% for the week, and stocks such as MINIMAX and Xunce experienced significant rebounds on May 22.
KELUN-B (06990.HK) will announce Phase 3 data for sac-TMT combined with pembrolizumab as a first-line treatment for PD-L1-positive advanced NSCLC (median PFS: NR vs. 5.7 months, $HR = 0.35$) and Phase 2 data for lemborertinib fumarate in RET fusion-positive NSCLC (ORR of 87.1% in pretreated patients) at the 2026 ASCO Annual Meeting. Both registration studies have been selected for oral presentations, and relevant marketing applications have been accepted by the NMPA.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that four of its pharmaceutical products have obtained production registration approvals from the NMPA. It is the second domestic enterprise to get approval for Emedastine Difumarate Eye Drops and the third for Perindopril Arginine Tablets. Peramivir Sodium Chloride Injection and Bumetanide Injection have also been approved, all deemed to have passed generic consistency evaluation.
NewTimeSpace News: Innovent Biologics (01801.HK) announced that the new drug application for the combination therapy of Tyvyt® (Sintilimab Injection) and Elunate® (Fruquintinib) has been approved by the NMPA. It is indicated for locally advanced or metastatic renal cell carcinoma in patients who failed prior VEGFR-TKI treatment and have not received first-line PD-1/PD-L1 inhibitors. This marks the 10th approved indication of Tyvyt®.
NewTimeSpace News: Hbm Holdings Limited (02142.HK) announced preclinical research findings of LET003, its next-generation ACVR2A/2B-targeted monoclonal antibody developed via the Hu-mAtrIx™ AI platform. Data revealed that combination therapy of LET003 and semaglutide delivers markedly enhanced fat reduction and effective lean mass preservation. The combined group achieved a 34.7% greater reduction in fat mass and a 5.7% rise in lean mass compared with semaglutide monotherapy.
NewTimeSpace News: TransThera Sciences (Nanjing), Inc. (02617.HK) announced that exploratory clinical findings of its core product tiengrtinib as monotherapy and in combination with atezolizumab for advanced solid tumors have been published in Nature Communications (Impact Factor=15.7). Clinical data show that the objective response rate (ORR) of tiengrtinib monotherapy reached 16.7%, while the combination regimen achieved an ORR of 22.6%. It demonstrated prominent efficacy in cholangiocarcinoma patients, with an ORR of 30.8% under monotherapy.
NewTimeSpace News: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK) announced that the drug registration application for Taohong Siwu Decoction Granules submitted by its controlling subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA). As a Class 3.1 new traditional Chinese medicine, the formulation originates from Fuke Bingjian by Qing-dynasty physician Chai Dehua and is included in the First Catalogue of Ancient Classic Prescriptions issued by the State Administration of Traditional Chinese Medicine.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the Phase I clinical trial of its self-developed HLX48 for injection, an EGFR/c-MET dual-target antibody-drug conjugate (ADC) for advanced/metastatic solid tumors, has been approved by the relevant Human Research Ethics Committee and completed clinical trial notification with Australia’s Therapeutic Goods Administration (TGA). No 同类 bispecific ADC has been approved globally so far.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that its self-developed HLX97, a KAT6A/B small-molecule inhibitor, has completed first patient dosing in China for the Phase I clinical trial in patients with advanced/metastatic solid tumors. The candidate is intended for the treatment of advanced and metastatic solid tumors, and no KAT6A/B small-molecule inhibitor has been approved worldwide to date.
NewTimeSpace News: Alphamab Oncology announced on May 13 that the Phase II clinical study of JSKN033, a high-concentration subcutaneous fixed-dose combination consisting of a HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer, has completed the first patient dosing.
NewTimeSpace News: Suzhou Riborn Biotech Co., Ltd. (06938.HK) announced that its core product vortosiran (RBD4059) has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE).Vortosiran is the world’s most advanced small nucleic acid drug targeting FXI. It has previously completed a Phase 2a clinical trial in Europe for coronary artery disease.
